Subscribe
shutterstock_1757758247_oasis2me
oasis2me / Shutterstock.com
8 March 2022BiotechnologyTakanori Abe

Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing

Issue: Report of the Japan Biosimilar Association

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.

More features

China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
10x Genomics counsel: ‘Winning cases is a top priority’